Open Access
Med Sci (Paris)
Volume 39, Number 2, Février 2023
Page(s) 101 - 104
Section Nouvelles
Published online 17 February 2023
  1. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007 ; 19 : 813–824. [CrossRef] [PubMed] [Google Scholar]
  2. Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 2018 ; 8 : 1069–1086. [CrossRef] [PubMed] [Google Scholar]
  3. Sharma P, Allison JP. Dissecting the mechanisms of immune checkpoint therapy. Nat Rev Immunol 2020; 20 : 75–6. [Google Scholar]
  4. Boutros C, Tarhini A, Routier E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 2016 ; 13 : 473–486. [Google Scholar]
  5. Johnson DB, Nebhan CA, Moslehi JJ, et al. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol 2022; 19 : 254–67. [Google Scholar]
  6. Ramos-Casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers 2020; 6 : 38. [Google Scholar]
  7. Meylan M, Petitprez F, Becht E, et al. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity 2022; 55 : 527–41.e5. [CrossRef] [PubMed] [Google Scholar]
  8. Mazor RD, Nathan N, Gilboa A, et al. Tumor-reactive antibodies evolve from non-binding and autoreactive precursors. Cell 2022; 185 : 1208–22.e21. [CrossRef] [PubMed] [Google Scholar]
  9. Shahabi V, Berman D, Chasalow SD, et al. Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events. J Transl Med 2013 ; 11 : 75. [Google Scholar]
  10. Barr TA, Shen P, Brown S, et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cells. J Exp Med 2012 ; 209 : 1001–1010. [CrossRef] [PubMed] [Google Scholar]
  11. Li R, Rezk A, Miyazaki Y, et al. Proinflammatory GM-CSF–producing B cells in multiple sclerosis and B cell depletion therapy. Sci Transl Med 2015; 7 : 310ra166–310ra166. [Google Scholar]
  12. Oleinika K, Mauri C, Salama AD. Effector and regulatory B cells in immune-mediated kidney disease. Nat Rev Nephrol 2019 ; 15 : 11–26. [Google Scholar]
  13. Catalán D, Mansilla MA, Ferrier A, et al. Immunosuppressive mechanisms of regulatory B cells. Front Immunol 2021; 12 : 611795. [CrossRef] [PubMed] [Google Scholar]
  14. Fridman WH, Meylan M, Petitprez F, et al. B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nat Rev Clin Oncol 2022; 19 : 441–57. [Google Scholar]
  15. Patel AJ, Willsmore ZN, Khan N, et al. Regulatory B cell repertoire defects predispose lung cancer patients to immune-related toxicity following checkpoint blockade. Nat Commun 2022; 13 : 3148. [Google Scholar]
  16. Khan AR, Hams E, Floudas A, et al. PD-L1hi B cells are critical regulators of humoral immunity. Nat Commun 2015 ; 6 : 5997. [Google Scholar]
  17. Ghosh N, Chan KK, Jivanelli B, et al. Autoantibodies in patients with immune-related adverse events from checkpoint inhibitors: A systematic literature review. J Clin Rheumatol 2022; 28 : e498–505. [CrossRef] [PubMed] [Google Scholar]
  18. Das R, Bar N, Ferreira M, et al. Early B cell changes predict autoimmunity following combination immune checkpoint blockade. J Clin Invest 2018 ; 128 : 715–720. [CrossRef] [PubMed] [Google Scholar]
  19. Isnardi I, Ng Y-S, Menard L, et al. Complement receptor 2/CD21 human naive B cells contain mostly autoreactive unresponsive clones. Blood 2010 ; 115 : 11. [Google Scholar]
  20. Fridman WH, Sibéril S, Pupier G, et al. Activation of B cells in tertiary lymphoid structures in cancer: Anti-tumor or anti-self? Semin Immunol 2023; 65 : 101703. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.